277 related articles for article (PubMed ID: 33254246)
1. [Endocrine side effects of cancer immunotherapy].
Kroiß M; Schilling B; Deutschbein T
Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
[TBL] [Abstract][Full Text] [Related]
3. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
Deligiorgi MV; Panayiotidis MI; Trafalis DT
Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
[TBL] [Abstract][Full Text] [Related]
4. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
6. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
[TBL] [Abstract][Full Text] [Related]
7. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
González-Rodríguez E; Rodríguez-Abreu D;
Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
[TBL] [Abstract][Full Text] [Related]
9. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
10. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
Griewing LM; Schweizer C; Schubert P; Rutzner S; Eckstein M; Frey B; Haderlein M; Weissmann T; Semrau S; Gostian AO; Müller SK; Traxdorf M; Iro H; Zhou JG; Gaipl US; Fietkau R; Hecht M
BMC Cancer; 2021 Mar; 21(1):314. PubMed ID: 33761922
[TBL] [Abstract][Full Text] [Related]
11. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
13. The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events.
Mihic-Probst D; Reinehr M; Dettwiler S; Kolm I; Britschgi C; Kudura K; Maggio EM; Lenggenhager D; Rushing EJ
Immunobiology; 2020 Sep; 225(5):152009. PubMed ID: 32962812
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
15. Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.
Boegeholz J; Brueggen CS; Pauli C; Dimitriou F; Haralambieva E; Dummer R; Manz MG; Widmer CC
BMC Cancer; 2020 Apr; 20(1):300. PubMed ID: 32290812
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
18. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
Cooksley T; Girotra M; Ginex P; Gordon RA; Anderson R; Blidner A; Choi J; Dougan M; Glezerman I; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6175-6181. PubMed ID: 32856213
[TBL] [Abstract][Full Text] [Related]
19. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
20. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.
Hsiehchen D; Watters MK; Lu R; Xie Y; Gerber DE
JAMA Netw Open; 2019 Sep; 2(9):e1911519. PubMed ID: 31532516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
